It is made available under a CC-BY-NC-ND 4.0 International license .

1 TITLE PAGE

- 2 **Title:** Temporal dynamics of skin microbiota and immune correlates in psoriasis patients
- 3 receiving systemic treatment
- 4 **Running title:** Microbiota, treatment, and responses in psoriasis
- 5 **Authors:** Su-Hsun Liu,^{a,b} Yu-Huei Huang,^{c,d} Hao-Jui Weng,^{e,f,g} Tsen-Fang Tsai,^{e,h} Huang-Yu
- 6 Yang,^{c,i} Leslie Y Chen,^j Yen-Ling Chiu,^k Hsiao-Yun Yu,^c Yi-Chieh Chiu,^b Chao-Yu Ng,^{c,d} Ya-
- 7 Ching Chang,^d Chung-Yee R Hui,^d Yhu-Chering Huang^l
- 8 Affiliations:
- 9 a. International Health Program, National Yang Ming University, Taipei, Taiwan
- 10 b. Health Management Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan
- 11 c. College of Medicine, Chang Gung University, Taoyuan City, Taiwan
- 12 d. Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- 13 e. Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan
- 14 f. Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical
- 15 University, Taipei, Taiwan
- 16 g. Department of Dermatology, Taipei Medical University- Shuang Ho Hospital, New Taipei
- 17 city, Taiwan
- 18 h. Department of Dermatology, School of Medicine, College of Medicine, National Taiwan
- 19 University, Taipei, Taiwan
- 20 i. Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- 21 j. Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- 22 k. Department of Nephrology, Far Eastern Memorial Hospital, New Taipei City, Taiwan
- 23 l. Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan

It is made available under a CC-BY-NC-ND 4.0 International license .

24	Correspondence author: Su-Hsun Liu, MD MPH PhD
25	Current affiliation: Department of Ophthalmology, University of Colorado Anschutz Medical
26	Campus, Aurora CO, USA
27	Email: suhsun.liu@cuanschutz.edu
28	
29	Funding sources: The current study was supported by Ministry of Science and Technology,
30	Taiwan [MOST 104-2314-B-182-002, 105-2628-B-182-006, 107-2314-B-418-015 to S Liu];
31	Chang Gung Medical Foundation [CMRPG3E1971-72 and BMRPE29 to S Liu]; Far Eastern
32	Memorial Hospital [FMRP107-2314B418015 to S Liu]. The funders had no role in preparing or
33	submitting the current work.
34	
35	Keywords: Skin microbiota (Microbiology), psoriasis, clinical outcomes, epidemiology (Cohort
36	study), biomarkers, systemic treatment
37	
38	Manuscript word count: abstract 284 (300); text 3077 (3000)
39	

40 **Figures and tables:** 2 figures and 4 tables

It is made available under a CC-BY-NC-ND 4.0 International license .

41 ABSTRACT

42 Background

43 How skin microbiota in psoriasis patients responded to systematic therapeutics remained

44 unknown.

45 **Objectives**

- 46 To profile temporal shifts in transcriptionally active skin microbiota in psoriasis patients
- 47 receiving systemic therapies.
- 48 Methods

49 We prospectively enrolled 61 psoriasis patients and 29 skin-healthy controls in 2015-2019.

50 Using RNA-based 16S rRNA gene sequencing, we analyzed 969 samples from skin lesions

51 and compared microbial abundance and diversity by therapeutic classes and disease severity.

52 **Results**

53 Lesional microbiota in patients on conventional systemics and TNF- α inhibitor was different 54 in relative abundances in Firmicutes (7.83% higher, adjusted P < 0.001) and Proteobacteria 55 (6.98% lower, adjusted P < 0.01) from that in patients on anti-interleukin monoclonal 56 antibodies (anti-ILAb) at baseline. The only difference during treatment was a 1.47% lower 57 abundance in Bacteroides associated with nonbiologics use (adjusted P < 0.01). We 58 identified no indicator taxa by disease severity at baseline yet noticed that a minor relative 59 reduction in Corynebacterium sp. was associated with clinical responses to treatment. 60 Compared to anti-ILAb, TNF- α inhibitor and nonbiologics were associated with -0.21 lower 61 Shannon Diversity (adjusted P < 0.01) and 0.03 higher Shannon Evenness (adjusted P < 0.01) 62 0.01). Results of ordinated principal coordinates analysis revealed that, lesional microbiota 63 from patients of these 3 therapeutic groups was compositionally distinct. Our work also

It is made available under a CC-BY-NC-ND 4.0 International license .

- 64 demonstrated concurrent changes in clonal shifts in systemic T cell receptor clonotypes that
- 65 were associated with systemic use of biologics.

66 Conclusions

- 67 Community abundances and diversities of skin microbiota may be useful in distinguishing
- 68 skin microbiota from patients receiving different systemic therapeutics. Specifically, use of
- 69 anti-ILAb and TNF- α inhibitor was associated with sample-wise microbial abundances and
- 70 diversities, but not richness, over time. These findings highlighted the potential utility of skin
- 71 microbiota as biomarkers for personalized treatment plans in patients with moderate-to-
- 72 severe psoriasis.

It is made available under a CC-BY-NC-ND 4.0 International license .

73 INTRODUCTION

74 Psoriasis vulgaris (psoriasis) is a chronic immune disease that manifests as well-defined 75 scaly skin plaques, which may be associated with arthritis and systemic comorbidities [1]. 76 Both innate immunity and T-cell response contribute to the disease pathogenesis, 77 constituting major therapeutic targets for effective systemic therapies [2]. Recently, skin 78 microbiota has emerged as novel candidate biomarkers for disease management [3, 4]. 79 Despite the proven clinical effectiveness of anti-psoriatic therapies, few studies have 80 examined therapy-specific influences on lesional microbiota longitudinally [5]. A recently-81 updated Cochrane review showed that biologics, including TNF- α inhibitor and anti-ILAb, 82 were more effective in achieving clinical remission as measured by PASI 90 (90% reduction 83 in Psoriasis Area and Severity Index relative to the baseline) than the small molecules and 84 conventional systemics in the trial setting [2]. However, whether and how conventional 85 therapies, TNF- α inhibitor, and anti-ILAb differentially alter the host microbiota in a non-86 trial setting remains unstudied. Besides, whether clinical responses were associated with any 87 shifts in lesional microbiota has not been well-characterized [3]. As such, we sought to 88 delineate relationships among systemic therapies, treatment responses, and characteristics of 89 lesional microbiota in psoriasis patients via serial sampling. Particularly, to reduce 90 environmental influences on the low biomass of skin samples [6] and to provide an in-depth 91 insight into the relevant responses to a newly-prescribed regimens [7, 8], we sought to 92 profile transcriptionally-active skin microbiota using bacterial 16S rRNA transcript 93 sequencing. We also explored temporal changes in T cell receptor (TCR) repertoire diversity 94 during treatment for a better understanding of treatment effects on the host immunity. 95

It is made available under a CC-BY-NC-ND 4.0 International license .

96 MATERIALS AND METHODS

97 Subject enrollment

- 98 Between May 2015 and November 2019, we enrolled and followed adults (aged 20 years or
- 99 older) with psoriasis at Dermatology Outpatient Clinics of two tertiary hospitals (Chang Gung
- 100 Memorial Hospital and National Taiwan University Hospital) in Taiwan. Patients were eligible
- 101 for study entry when initiating new systemic therapy; majority of the washout period was > 4
- 102 weeks. We excluded those with a recent exposure to topical or systemic antibiotics,
- 103 immunosuppressants, or chemotherapies within 12 weeks prior to study enrollment. In 2016-
- 104 2019, we also recruited skin-healthy adults who did not have diagnoses of chronic inflammatory

skin disorders but either visited the same clinics for mole excision or alopecia treatment, or were

- 106 care givers of the index patients. Center-specific Institution Review Boards reviewed and
- approved the study protocols, separately (CGMH 103-6837B, 104-9746B, 201702308B0C501;

108 NTUH 201809061RINB).

109

110 Data and sample collection

After obtaining written informed consent, well-trained research assistants conducted in-person interviews to collect sociodemographic information, medical history, and behavioral habits. Patients also reported quality of life and anxiety/depressive symptoms using Dermatology Life Quality Index (DLQI)[9] questionnaire and Center for Epidemiologic Studies Depression Scale (CESD-S)[10] at baseline and follow-up visits. According to European S3-Guidelines [11], we grouped patients by non-biologics (acitretin, cyclosporin, methotrexate); anti-interleukin monoclonal antibodies (anti-ILAb: ustekinumab, secukinumab, ixekizumab, and guselkumab);

It is made available under a CC-BY-NC-ND 4.0 International license .

118	tumor necrosis factor- α antagonists (TNF- α inhibitor: adalimumab, golimumab, and etanercept).
119	Treatment responses were absolute PASI scores and PASI 75 responses.
120	
121	To profile skin microbiota from sequencing 16S rRNA gene transcripts, we used Tween20-
122	moistened FLOQSwabs (Copan, Murrieta, CA, USA) to collect scrapes over an area of 2 x 2 cm ²
123	on pre-specified surfaces with active lesions [12, 13], including bilateral scalp, post-auricular
124	hairlines, extensor forearms, pretibial shafts, and palms; these sampling sites also applied to skin-
125	healthy controls. To facilitate swab collection, we requested the study participants to refrain from
126	bathing or body scrubbing at least 24 hours prior to a study visit. We also encouraged each
127	participant to cover up sampling sites with cotton-made clothing to reduce environmental
128	influences while in the study.
129	
130	16S rRNA gene transcript isolation, amplification, sequencing, and processing
131	We performed RNA isolation by firstly disrupting bacterial cell walls in a chemical lysis buffer
132	[7]. Reverse transcription of total RNA immediately followed the recovery of RNA samples
133	using the SuperScript RT-PCR kit (Invitrogen, Carlsbad, CA, USA) according to the
134	manufacturer's manual. For each PCR sample, we confirmed the presence of amplicons by gel
135	electrophoresis. We included 2-3 negative controls for each library preparation as suggested in
136	the literature [14, 15], and mock community DNA (Zymo Research, Irvine, CA, USA) as
137	positive controls [16].
138	
139	We applied 'mothur' (version 1.43.0) to the raw sequence reads using a modified reference

region for sequence alignment [17, 18] and clustered the filtered reads into operational taxonomy

It is made available under a CC-BY-NC-ND 4.0 International license .

141 units (OTU) at 97% identify before subsequent statistical analysis and graphing in R (v 4.0.2)

142 [19]. Using R packages 'decontam' and 'phyloseq' [15, 20], we identified and removed potential

143 contaminant taxa inferred from 63 negative control samples [21], singletons, and samples with

144 low coverage (< 400 reads/ sample). In total, we included 969 samples (82.0% of sequenced

samples) with a median of 43 577 reads per sample (interquartile range [IQR]: 33 987-55 972) in

146 the following analysis.

147

148 **TCR** repertoire profiling

149 We collected peripheral blood samples in EDTA tubes from 9 anti-ILAb users before and 12

150 weeks after treatment began. We also collected 1 blood sample from 7 skin-healthy participant at

151 baseline. Using flow cytometry, we sorted CD3+ T cells, from which RNA isolation was

152 performed by employing RNeasy Mini Kit (Qiagen). Procedures of the library preparation

153 included nested amplifications targeting the V-C regions of the complementarity-determining

154 region (CDR3) of TCR using TCR $\alpha\beta$ kits (iRepertoire, Huntsville, AL, USA).

155

156 Statistical Analysis

157 Patient data. We described and compared baseline participants' characteristics by disease status

and therapy class (patients only) using median tests for independent continuous variables and

159 Chi-squared or Fisher's exact test for categorical ones. We tested our hypothesis using

160 multivariable quantile regression analysis with robust or bootstrapped (3 000 replicates) variance

- 161 estimation to account for repeated measures. All longitudinal data analysis considered
- 162 observations over the 12-15 weeks of follow-up period to allow for sufficient statistical power.

It is made available under a	CC-BY-NC-ND	4.0 International licens	se
------------------------------	-------------	--------------------------	----

163	We used Stata-MP (Version 13.1) with a 2-tailed significance of 0.01 for comparative analysis
164	[22], and employed R packages 'ggplot2' and 'vegan' for graphics production [23, 24].
165	
166	<i>Microbiota data.</i> We calculated α -diversity measures of richness (observed number of unique
167	OTUs, Chao1 index), Shannon diversity (ShannonD) and Shannon evenness (ShannonE) indices
168	for quantifying within-sample variation. Based on non-metric and linear R ² values, we chose
169	Bray-Curtis dissimilarity index to compare between-sample distance matrices [25]. We
170	performed hypothesis testing via permutational multivariate analysis of variance
171	(PERMANOVA, 10 000 permutations) [26]. We also repeated relevant analysis using read-based
172	rarefied datasets; the results did not alter our conclusions.
173	
174	TCR profiling. We performed descriptive analysis by sample and patient characteristics;
175	compared differences in the normalized usage of V- and J-segment of the CDR3 gene, and in
176	diversity metrics of CDR3 clonotypes using bootstrapped quantile regression models to estimate
177	the empirical variance (3 000 replicates) in Stata-MP (Version 13.1) [22]. We applied a 2-tailed
178	significance level of 0.05 for exploratory analysis on gene expression and TCR sequence data.
179	
180	Data Availability
181	We have deposited raw sequences of 16S rRNA transcripts and TCR transcripts to the Short
182	Read Archive (SRA) database under the BioProject accession number PRJNA662768.
183	
184	RESULTS
185	Study population

It is made available under a CC-BY-NC-ND 4.0 International license .

186 We prospectively enrolled and followed 119 participants for 12 weeks or longer between 2015 187 and 2019. Ten patients received an extended observation for additional 6 months while receiving 188 maintenance biologics therapy (Fig. S1). We included 743 and 226 quality swabs from 61 189 psoriasis patients and 29 controls who returned at least once within 16 weeks in the current 190 analysis (follow-up rate: 87% and 83%). The patient population comprised mainly of men (87%) 191 (median age: 43 years) with an average disease duration of 23 years (IQR: 19-33). There were no 192 statistical differences in patient characteristics associated with therapeutic classes at study entry. 193 In total, 79% of patients had moderate-to-severe psoriasis; all patients of the 3 therapeutic groups 194 began with comparable disease severity at study entry (Table 1). Patients excluded based on low-195 quality sequencing samples (N=5) were comparable to those included in the current analysis 196 (Table S1). 197 198 At 12-15 weeks after treatment began, disease activity in all patients declined significantly, with 199 the median PASI score decreasing from 15 (IQR: 11-20) to 4 (IQR: 1-8) (adjusted P for trend < 200 0.001). Patients in each therapeutic class had comparable trends in disease activities over time; 201 there were no significant differential group effects (all P for interaction tests > 0.01). Self-202 reported DLQI also decreased substantially from 9 (IQR: 4-15) at baseline to 2 (0-8, adjusted P 203 for trend < 0.001) whereas self-reported anxiety symptoms as quantified by CESD scores did not 204 vary over time (Table S2). 205

206 Normal versus lesional microbiota

207 *Microbial abundances.* At study entry, phylum abundances in normal skin microbiota were

208 statistically comparable to those in lesional microbiota with or without accounting for

It is made available under a CC-BY-NC-ND 4.0 International license .

209	participants' age, sex, absence of prior treatment, and year of enrollment (Table 2). A relative
210	dominance of Proteobacteria in lesional microbiota by 3.35% (95%CI: 1.44%, 5.25%) emerged
211	over time (adjusted $P < 0.001$); simultaneous comparisons across disease status and sampling
212	sites revealed similar results (adjusted P=0.002, Fig. S2a). Likewise, we examined abundances of
213	the most common 6 genera as suggested in the literature [27] (Fig. S2b), and found no evidence
214	for indicator taxa between lesional and normal skin (Table S3).
215	
216	Despite an over-representation of men in the patient group, results of sex-specific comparisons
217	between lesional and normal microbiota were alike at baseline but not longitudinally, during
218	which a relative over-abundance of Proteobacteria was significant in samples from male patients
219	by 4.13% (95%CI: 1.88%, 6.38%) as compared to normal skin (Table 2). Formal tests for disease
220	status-by-sex interaction were nonsignificant. Additional stratified analysis by the absence of
221	prior treatment found no significant subgroup effects either.
222	
223	Microbial alpha- & beta-diversity. When compared to healthy skin, psoriatic lesions had
224	resembling microbial richness and diversity before and during treatment; only the degree of
225	community evenness (all unique taxa showing equal abundances) was lower in lesional than
226	normal microbiota (adjusted P=0.01; Table S4). Correspondingly, results of Bray-Curtis
227	distance-based PCoA showed an overall community similarity between the two groups
228	(PERMANOVA P > 0.05, Fig. S2c).
229	

230 Lesional microbiota, clinical treatment, and responses

It is made available under a CC-BY-NC-ND 4.0 International license .

231	Microbial abundances. Before initiating new therapies, lesional microbiota of patients using
232	non-biologics had 7.83% more Firmicutes (95%CI: 4.26%, 10.5%) than those using anti-ILAb
233	(adjusted P< 0.001) whereas TNF- α inhibitor was associated with a 6.98% lower abundance
234	(95%CI: -12.2%, -1.73%) in Proteobacteria than anti-ILAb (Table 3). Over time, psoriatic
235	lesions in non-biologics users showed a relative 1.47% reduction (95%CI: -2.49%, -0.45%) in
236	Bacteroidetes as compared to anti-ILAb users while losing the dominance of Firmicutes
237	(adjusted P>0.01, Fig. S3). Abundances in the four major phyla did not differ by initial disease
238	severity or patients' clinical responses as indicated by PASI 75 at follow-up (Table 3).
239	
240	Stratified analysis by prior treatment history revealed a higher abundance of Firmicutes in
241	nonbiologics-associated samples from patients with previous treatment history (6.93%, 95% CI:
242	5.84%, 8.02%) but a lack thereof in those who were treatment-naïve. Similarly, subgroup
243	analysis by sex showed a significant reduction in Proteobacteria (-17.5%, 95%CI: -29.0%, -6.1%)
244	in women using TNF- α inhibitor as compared to anti-ILAb but no statistical differences by
245	therapy group in men.
246	
247	At genus levels, Staphylococcus sp. was more abundant in samples from the non-biologics group
248	than the anti-ILAb group (adjusted P< 0.001) at baseline. There were no significant differential
249	abundances by baseline disease severity (PASI $>$ 10). Longitudinally, classes of systemic
250	therapies were not associated with any indicator genera considered. Instead, lesions of PASI 75
251	responders had a 0.38% decrease in Corynebacterium sp. but nonsignificant differences in other
252	genera relative to poor responders (Table S5).

253

It is made available under a CC-BY-NC-ND 4.0 International license .

254 *Microbial alpha- & beta-diversity.* Before treatment began, α -diversity measures of skin 255 microbiota appeared comparable among samples from the three therapeutic groups, or by initial 256 degrees of disease severity (Table 4). During the follow-up period, we noted a significant 257 decrease (-0.21; 95% CI: -0.37, -0.06) and increase (0.03; 95% CI: 0.01, 0.06) in Shannon D and 258 Shannon E of the TNF- α inhibitor group and the non-biologics group relative to the reference 259 group, separately (Fig. 1a). Results of distance-based analysis of variance suggested significant 260 pair-wise dissimilarities between samples from healthy skin microbiota and lesional microbiota 261 of patients receiving anti-ILAb or TNF- α inhibitor (both permuted P < 0.001, Fig. 1b). On the 262 other hand, samples from non-biologics users and healthy controls were compositionally similar 263 as shown in unconstrained PCoA (Fig. S4a). Again, sample-wise α -diversity measures in PASI 264 75 responders and poor responders were indistinguishable during treatment (Table 4), wherefore 265 these results were compatible to results of β -diversity analysis (Fig. S4b).

266

267 Clonal shifts of TCR during treatment

268 In TCR analysis, we included sequencing results of 8 samples with 4157 (amino acid sequence) 269 unique CDR3 clonotypes (IQR: 2282 - 5642) identified per sample. The average D50 value was 270 2.8% (IQR: 2.1%-3.2%), suggesting that the most abundant 131 clonotypes accounted for 50% 271 of the total sample reads; there were no statistical differences in D50 values by disease status at 272 baseline (median difference: 0.9%, 95% CI: -4.5%, 6.3%). Shannon Diversity index of TCR 273 repertoire in psoriasis patients varied little after treatment (Table S6). We also showed that, 274 among 10 out of 13 J- and 48 V-segment genes, treatment-associated changes were significant 275 for segment hTRBJ1-6 (+0.9%, 95%CI: 0.4%, 1.4%), hTRBJ2-6 (+1.4%, 95%CI: 0.3%, 2.5%),

medRxiv preprint doi: https://doi.org/10.1101/2023.11.27.23298999; this version posted November 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

and hTRBV3-1 (-0.7%, 95%CI: -1.4%, -0.03%) in after- versus before-treatment comparisons
among psoriasis patients (Fig. 2).

278

279 **DISCUSSION**

280 In this prospective cohort study, we showed that, transcriptionally-active skin microbiota in 281 psoriasis patients of 3 major therapeutic classes displayed distinctive community abundances and 282 diversities before and after treatment. Over the past decade, the well-debated observations that 283 TNF- α inhibitor could increase patients' risks for severe infections [28, 29], such as reactivation of latent tuberculosis [30, 31], and the less-debated low risks of similar adverse events in patients 284 285 receiving IL-17A or IL-12/23p40 inhibitor [32, 33], have led to our hypothesized differential 286 effects of systemic therapies on lesional microbiota. Since both biologics lead to a common, 287 downregulated secretion of cytokines, chemokines, and AMPs, such β -defensins and S100 288 proteins [12], we anticipated starker contrasts between lesional microbiota in biologics and 289 nonbiologics users than between samples from patients receiving different biologics. The 290 observation that only results of β -analysis conformed with our conjectures, alluded the multi-291 dimensional complexity in quantifying (dis)similarities among groups of surveyed human 292 microbiota [21].

293

294 Besides specific immune perturbations inflicted on lesional microbiota by different therapies, the

295 initial community structure may partially account for the group differences observed

296 longitudinally. For instance, non-biologics users had the highest relative abundance of

297 Firmicutes (25.8%, IQR: 22.1%, 29.4%) at baseline (anti-ILAb: 20.3%; TNF- α inhibitor: 21.8%),

298 yet their lesional microbiota also followed a significant decline temporally (in Firmicutes, -

It is made available under a CC-BY-NC-ND 4.0 International license .

0.06% per day, 95%CI: -0.09%, -0.02%). Rates of changes in the other 2 treatment groups
remained nonsignificant, leading to a consensus post-treatment state across the comparison
groups. Contrary to the other two groups, samples from anti-ILAb patients showed evident
stability in community abundances, richness, and diversity over the treatment period, rendering
the group as an optimal reference for within-patient comparisons.

304

305 Our findings that the relative ranking in normalized usage of TCR segments TRBV3-1, V9, and 306 V11-2 examined in the current study, agreed with an early investigation by Tsuda et al. in 307 evaluating effects of ustekinumab on the presence or absence of TRB V-segments in psoriasis 308 patients [34]. These transcriptional shifts in selective CDR3 clonotypes (31% of 13 J-segments, 309 13% of 48 V-segments) of circulating T cells in patients receiving IL-12/-23 or IL-17A 310 monoclonal antibodies suggested host systemic responses in T cell differentiation after 12-week 311 exposure to blockade against the Th1/Th17 axis. Whether these transitions in TCR clonality 312 resulted from direct depletion of associated lineages or indirect responses to a re-shaping of skin 313 microbiota, was beyond the study's scope. 314 315 Conversely, the notion that characteristics of lesional microbiota were not linked to pre-treatment

316 disease severity, was contrary to a previously-reported negative correlation found between

317 baseline absolute PASI score and Shannon Diversity. In a pre-post study on effects of UVB

318 treatment, Assarsson and colleagues found that there were no similarly positive relationships

319 between disease severity and microbial diversity after treatment [35]. Although Corynebacterium

sp. has been implicated in IL-1 β production and expansion of $\gamma \delta T_{17}$ cells in inflammatory skin

321 conditions of model animals [36], our finding that a minor decrease in *Corynebacterium* sp. was

medRxiv preprint doi: https://doi.org/10.1101/2023.11.27.23298999; this version posted November 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

322 associated with clinical responses during treatment, warrants additional research to confirm its323 potential clinical utility.

324

325	Although the observation that normal skin harbored fewer Proteobacteria than lesional
326	microbiota, was inconsistent with previous findings [13, 37], such cross-study inconsistency has
327	been well-recognized in the literature [27]. Potential sources of disagreements may include
328	heterogeneous patient characteristics under different investigations; choices of analytic
329	approaches; intrinsic discrepancies in DNA- vs. RNA-based profiling of bacterial 16S rRNA
330	genes of skin microbiota. Particularly, Belheouane and others compared the murine ear skin
331	microbiota of standing and active microbial communities using 16S rRNA genes and transcripts
332	sequence data, respectively, and concluded that, RNA- was better than DNA-based profiling in
333	reducing environmental contaminations [6]. Given that comparisons in microbial abundances
334	and α diversity measures between DNA- and RNA-based methods may not always agree with
335	each other even within the same study [8, 14, 38, 39], between-study heterogeneities can be
336	expected; nonetheless, comparative results obtained by either technique shall remain valid within
337	each study [14].

338

339 Limitations

A few limitations are noteworthy in the current analysis. First, as an observational study, we did not specify group sizes for each treatment group *a priori*; restrictions on funding also precluded extended recruitment. The impacts of unequal group sizes and the broad-ranging grouping of patients receiving conventional systemics or anti-ILAb, were uncertainties and possibly attenuated associations. As such, results of comparisons by therapeutic class required careful

It is made available under a CC-BY-NC-ND 4.0 International license .

345 interpretation and generalization. According to a population-based patient registry in Sweden, 346 female patients generally had a lower PASI score than male patients across the age groups [40]. 347 Since the current study sought to enroll patients with moderate-to-severe psoriasis, the 348 predominance of men in our patient population was expected and the sex-adjusted comparison 349 results within the patient population remained relevant and valid, particularly to those receiving 350 systemic treatment. Although proportions of patients receiving different systemic therapeutics 351 did not differ substantially across the recruitment waves, microbial structure, and diversity of 352 lesional microbiota may be conditioned by patients' prior treatment, of which we used a proxy 353 variable (the absence of prior treatment) for statistical adjustment; the reported associations were 354 indeed weighted averages of a heterogeneous patient population. Lastly, we recognized the 355 challenges of low biomass even on skin lesions and attempted to sequence cDNA sequences of 356 16S amplicons instead of the corresponding DNA sequences directly. How this unique approach 357 could have resulted in biased representations of certain Phyla has not been well characterized 358 [41]. Future studies that collect detailed information on serial medications, may provide novel 359 insights on the long-term trajectories of therapeutic effects on the lesional microbiota.

360

361 CONCLUSIONS

The current study showed that, classes of systemic therapies were independently associated with characteristics of lesional microbiota in adult psoriasis patients enrolled in a non-trial setting. These findings may support for the clinical utility of transcriptionally-active skin microbiota as biomarkers for tailoring systemic therapies to patients with moderate to severe psoriasis in addition to the absolute PASI scores.

It is made available under a CC-BY-NC-ND 4.0 International license .

367 CONFLICTS OF INTEREST

- 368 The authors declared no conflicts of interests.
- 369

370 FUNDING SOURCES

- 371 The study was supported by Ministry of Science and Technology, Taiwan [MOST 104-2314-B-
- 372 182-002, 105-2628-B-182-006, 107-2314-B-418-015 to S Liu]; Chang Gung Medical
- 373 Foundation [CMRPG3E1971-72 and BMRPE29 to S Liu]; Far Eastern Memorial Hospital
- 374 [FMRP107-2314B418015 to S Liu]. The funders had no role in preparing or submitting the
- 375 current work.
- 376

377 AUTHOR CONTRIBUTIONS

- 378 Dr. S Liu had full access to all the data in the study and takes responsibility for the integrity of
- the data and accuracy of the reported findings.
- 380 Concept and design: S Liu, YH Huang, T Tsai
- 381 Acquisition, analysis, and interpretation of data: S Liu, YH Huang, H Weng, T Tsai, H Yu, YC
- 382 Chiu
- 383 Drafting of the manuscript: S Liu, H Weng
- 384 *Critical revision of the manuscript for important intellectual content:* S Liu, H Weng, T Tsai,
- 385 YH Huang
- 386 Statistical analysis: S Liu
- 387 Administrative, technical, or material support: HY Yang, L Chen, YL Chiu, HY Yu, YC Chiu,
- 388 C Ng, Y Chang, C Hui, YC Huang
- 389 Supervision: S Liu

It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES

[1] Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA : the journal of the American Medical Association. 2020;323; 1945-1960.

[2] Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane database of systematic reviews (Online). 2020;1; Cd011535.

[3] Niemeyer-van der Kolk T, van der Wall HEC, Balmforth C, Van Doorn MBA, Rissmann R. A systematic literature review of the human skin microbiome as biomarker for dermatological drug development. Br J Clin Pharmacol. 2018;84; 2178-2193.

[4] Harkins CP, Kong HH, Segre JA. Manipulating the Human Microbiome to Manage Disease. JAMA : the journal of the American Medical Association. 2019.

[5] Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, et al. Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. The Journal of investigative dermatology. 2018;138; 1973-1981.

[6] Belheouane M, Vallier M, Čepić A, Chung CJ, Ibrahim S, Baines JF. Assessing similarities and disparities in the skin microbiota between wild and laboratory populations of house mice. The ISME journal. 2020.

[7] Yuan S, Cohen DB, Ravel J, Abdo Z, Forney LJ. Evaluation of methods for the extraction and purification of DNA from the human microbiome. PloS one. 2012;7; e33865.

[8] Knecht H, Neulinger SC, Heinsen FA, Knecht C, Schilhabel A, Schmitz RA, et al. Effects of beta-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea. PloS one. 2014;9; e89417.

[9] Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19; 210-216.

[10] Radloff LS. The CES-D Scale: A Sef-Report Depression Scale for Research in the General Population. Applied Psychological Measurement. 1977;1; 385-401.

[11] Nast A, Jacobs A, Rosumeck S, Werner RN. Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29; e1-22.

[12] Nestle FO, Kaplan DH, Barker J. Mechanism of Disease: Psoriasis. New England Journal of Medicine. 2009;361; 496-509.

[13] Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome. 2013;1; 31. It is made available under a CC-BY-NC-ND 4.0 International license .

[14] von Rosenvinge EC, Song Y, White JR, Maddox C, Blanchard T, Fricke WF. Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota. The ISME journal. 2013.

[15] Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. Microbiome. 2018;6; 226.

[16] Kong HH, Andersson B, Clavel T, Common JE, Jackson SA, Olson ND, et al. Performing Skin Microbiome Research: A Method to the Madness. The Journal of investigative dermatology. 2017.

[17] Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dualindex sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Applied and environmental microbiology. 2013;79; 5112-5120.

[18] Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic acids research. 2013;41; D590-596.

[19] Team RC. R: A language and environment for statistical computing. 3.6.2 ed. Vienna, Austria. R Foundation for Statistical Computing, 2020.

[20] McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PloS one. 2013;8; e61217.

[21] Knight R, Vrbanac A, Taylor BC, Aksenov A, Callewaert C, Debelius J, et al. Best practices for analysing microbiomes. Nature reviews Microbiology. 2018;16; 410-422.

[22] StataCorp LP. Stata Statistical Software: Release 13. 13.1 ed. College Station, TX, 2013.

[23] Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, USA. Springer-Verlag. 2009.

[24] Oksanen J, Guillaume B, Friendly M, Kindt R, Legendre P, McGlinn D, et al. vegan: Community Ecology Package. R package version 2.5-6., 2019.

[25] Magurran AE, McGill BJ. Biodiversity: frontiers in measurement and assessment. United States. Oxford University Press. 2011.

[26] Anderson MJ. Distance-based tests for homogeneity of multivariate dispersions. Biometrics. 2006;62; 245-253.

[27] Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nature reviews Microbiology. 2018;16; 143-155.

It is made available under a CC-BY-NC-ND 4.0 International license .

[28] Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA : the journal of the American Medical Association. 2011;306; 2331-2339.

[29] Dobry AS, Quesenberry CP, Ray GT, Geier JL, Asgari MM. Serious infections among a large cohort of subjects with systemically treated psoriasis. J Am Acad Dermatol. 2017;77; 838-844.

[30] Sanchez-Moya AI, Garcia-Doval I, Carretero G, Sanchez-Carazo J, Ferrandiz C, Herrera Ceballos E, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2013;27; 1366-1374.

[31] Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. J Am Acad Dermatol. 2017;76; 299-308.e216.

[32] Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J. Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. The British journal of dermatology. 2017;176; 594-603.

[33] Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34; 1449-1456.

[34] Tsuda K, Yamanaka K, Kondo M, Matsubara K, Sasaki R, Tomimoto H, et al. Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity. PloS one. 2012;7; e51819.

[35] Assarsson M, Duvetorp A, Dienus O, Soderman J, Seifert O. Significant Changes in the Skin Microbiome in Patients with Chronic Plaque Psoriasis after Treatment with Narrowband Ultraviolet B. Acta dermato-venereologica. 2018;98; 428-436.

[36] Quan C, Chen XY, Li X, Xue F, Chen LH, Liu N, et al. Psoriatic lesions are characterized by higher bacterial load and imbalance between Cutibacterium and Corynebacterium. J Am Acad Dermatol. 2020;82; 955-961.

[37] Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res. 2012;304; 15-22.

[38] Rausch P, Basic M, Batra A, Bischoff SC, Blaut M, Clavel T, et al. Analysis of factors contributing to variation in the C57BL/6J fecal microbiota across German animal facilities. International journal of medical microbiology : IJMM. 2016;306; 343-355.

It is made available under a CC-BY-NC-ND 4.0 International license .

[39] Twomey KB, Alston M, An SQ, O'Connell OJ, McCarthy Y, Swarbreck D, et al. Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation. PloS one. 2013;8; e82432.

[40] Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol. 2017;18; 583-590.

[41] Chen Y, Knight R, Gallo RL. Evolving approaches to profiling the microbiome in skin disease. Front Immunol. 2023 Apr 4;14:1151527. doi: 10.3389/fimmu.2023.1151527.

It is made available under a CC-BY-NC-ND 4.0 International license .

1 Figure Legends

- 2 Fig 1a. Alpha diversity measures for quantifying within-sample microbial richness (OTU,
- 3 Chao1), diversity (Shannon D), and compositional evenness (Shannon E) in samples from
- 4 healthy controls and psoriasis patients in the 3 therapeutic classes. Over the study period,
- 5 significant differences included a relative decrease and increase in Shannon D and Shannon E in
- 6 samples associated with TNF- α Inhibitor and nonbiologics as compared to anti-ILAb (adjusted

7 P<0.01).

8

Fig 1b. Principal coordinates analysis of genus-level community data from patients of different therapeutic class. Based on 10^4 permutations, pairwise comparisons of distances between group centroids (solid circles) revealed significant community dissimilarities between TNF- α Inhibitor and anti-ILAb patients (P <0.001) or nonbiologics patients (P < 0.001) as well as between nonbiologics and anti-ILAb users (P < 0.01).

- 14 **Fig 2.** Boxplots of selected hTRB-V and -J segments with significant differential usage in
- 15 peripheral CD3+ T-cells between skin-healthy controls and psoriasis patients at baseline (T0)
- 16 and those at 12-15 weeks after anti-ILAb treatment began (T2). Normalized usage was the
- 17 proportion of each segment being identified in all CDR3 clonotypes of a given sample; the copy
- 18 number of each clonotype was not taken into account in order to avoid the influence of clonal
- 19 expansion on estimating sample-specific segment usage. Usage of segment hTRBJ1-2
- 20 (difference: 2.2%, 95%CI: 1.8%, 2.6%) and hTRBV9 (difference: 4.3%, 95%CI: 1.0%, 7.6%)
- 21 were significantly higher in healthy controls than in psoriasis patients before treatment. In
- contrast, the normalized usage of hTRBJ2-7 (difference: 11.5%, 95%CI: 2.1%, 20.9%),
- 23 hTRBV11-2 (difference: 1.5%, 95%CI: 1.1%, 1.9%), and hTRBV27 (difference: 1.3%, 95%CI:
- 24 0.8%, 1.8%) were statistically higher in psoriasis patients than in controls. NS, non-significant; *:
- 25 P<.05; **: P<.01; ***: P<.001.

Characteristics, %	Psoriasis Patients			P-	Skin-healthy Controls	P-
	Non-biologics (N=6)	TNF-α Inhibitors (N=13)	Anti-ILAbs (N=42)	value ^a	(N=29)	value ^b
Follow-up time (days), Median (IQR)	98 (77-112)	103 (94-119)	108 (84-112)	0.318	84 (84-91)	< 0.001
Age (years), Median (IOR)	41 (37-44)	40 (32-58)	44 (35-52)	0.318	51 (45-58)	0.006
20-36	17%	46%	29%	0.189	3%	0.003
36-50	83%	23%	43%		45%	
\geq 50	0	31%	29%		52%	
Male	100%	92%	83%	0.587	62%	0.007
BMI (Kg/m ²), Median (IQR)	27.3 (26.8-33.0)	28.7 (26.3-30.7)	27.7 (25.9-29.7)	0.450	24.7 (23.1-26.2)	< 0.001
WC (cm) ^c , Median (IQR)	96 (91-102)	97 (93-108)	92 (82-100)	0.240	79 (76-85)	< 0.001
Education ^c						
Less than high school	0	23%	36%	0.183	17%	0.421
High or vocational school	43%	23%	38%		34%	
College or higher	57%	54%	26%		45%	
Disease duration (years), Median (IQR)	22 (20-36)	21 (20-33)	26 (19-33)	0.422	-	-
Treatment-naive	57%	23%	29%	0.546	-	-
Regular alcohol use	14%	23%	24%	0.545	21%	0.946
Regular smoking					N=28	
Never	29%	77%	55%	0.284	79%	0.040
Quitted	0	0	12%		10%	
Yes	71%	23%	33%		10%	
Regular use of antiseptics for						
Face ^d	14%	8%	2%	0.226	0	0.551
Hand ^e	0	15%	7%	0.755	7%	1.000
Staphylococcal colonization						
Lesion/ skin	57%	23%	31%	0.507	7%	0.015
Nares	43%	15%	19%	0.211	7%	0.130
Clinical Outcomes						
PASI, Median (IQR)	15 (14-20)	13 (11-17)	15 (11-24)	0.698^{a}	-	
DLQI, Median (IQR)	12 (8-22)	9 (4-14)	10 (3-15)	0.796 ^a	-	

0.431^a

Abbreviations: BMI, body mass index; CESD, Center for Epidemiologic Studies Depression Scale; DLQI, Dermatology Life of Quality Index; anti-IL-Abs, anti-interleukin monoclonal antibodies; IQR, interquartile range; PASI, psoriasis area severity index; WC, waist circumference

13 (11-20)

a. P-value for median test; Chi-square test, or Fisher's exact test among psoriasis patients using different treatment regimens

b. P-value for median test; Chi-square test, or Fisher's exact test between psoriasis patients and control subjects

c. One healthy control had missing data

d. Three control subjects had missing data

e. Three control and 1 psoriasis participants had missing data

Relative Baseline (Cross-sectional model)		Baseline to 12-15 wk (Longitudinal model)		
Abundances (%)	Unadjusted	Adjusted ^a	Unadjusted	Adjusted ^a
Overall	beta (95%CI)	beta (95%CI)	beta (95%CI)	beta (95%CI)
Proteobacteria	0.03 (-0.00, 0.06)	4.54 (0.33, 8.75)b	2.35 (0.58, 4.11)c	3.35 (1.44, 5.25)d
Firmicutes	-0.01 (-0.03, 0.02)	-0.11 (-2.09, 1.88)	-0.78 (2.14, 0.58)	-0.24 (-1.91, 1.42)
Actinobacteria	-0.01 (-0.02, -0.00)b	-1.15 (-2.73, 0.44)	-1.07 (-1.97, -0.18)b	-0.94 (-2.11, 0.23)
Bacteroidetes	-0.002 (-0.01, 0.01)	-0.55 (-2.20, 1.10)	-0.32 (-1.06, 0.43)	-0.15 (-1.49, 0.59)
Men				
Proteobacteria	4.28 (0.89, 7.67)b	5.30 (0.24, 10.4)b	2.66 (0.64, 4.68)c	4.13 (1.88, 6.38)d
Firmicutes	-1.12 (-3.90, 1.65)	0.04 (-2.13, 2.21)	-0.72 (-2.45, 1.01)	-0.97 (-2.43, 0.48)
Actinobacteria	-1.33 (-2.70, 0.04)	-0.88 (-2.71, 0.96)	-1.64 (-2.71, -0.57)c	-0.87 (-2.18, 0.45)
Bacteroidetes	-0.25 (-1.78, 1.29)	-0.49 (-2.33, 1.36)	-0.44 (-1.43, 0.55)	-0.19 (-1.46, 1.08)
Women				
Proteobacteria	0.97 (-5.71, 7.65)	-4.61 (-14.4, 5.19)	0.53 (-3.78, 4.85)	-0.64 (-6.77, 5.49)
Firmicutes	-0.08 (-5.81, 5.66)	5.08 (-5.54, 15.7)	-2.15 (-4.95, 0.64)	-0.23 (-3.99, 3.53)
Actinobacteria	-1.00 (-3.31, 1.32)	-0.88 (-4.47, 2.70)	-0.63 (-2.20, 0.93)	-0.97 (-2.82, 0.87)
Bacteroidetes	0.16 (-2.39, 2.70)	-0.10 (-4.08, 4.06)	0.16 (-1.15, 1.47)	-0.16 (-1.84, 1.53)
With prior treatment				
Proteobacteria	1.55 (-2.26, 5.36)	-0.12 (-5.69, 5.45)	3.41 (1.67, 5.15)d	2.37 (-0.34, 5.08)
Firmicutes	2.16 (0.29, 4.03)b	1.16 (-1.91, 4.24)	0.57 (-0.82, 1.96)	-0.22 (-2.07, 1.64)
Actinobacteria	-0.89 (-2.53, 0.74)	-2.03 (-3.92, -0.13)b	-0.98 (-2.50, 0.54)	-1.41 (-2.99, 0.16)
Bacteroidetes	1.32 (0.21, 2.42)	0.47 (-1.38, 2.32)	0.42 (-0.70, 1.54)	0.24 (-1.07, 1.56)

Table 2. Differences in phylum-level relative abundance between lesional and healthy skin microbiota at baseline and during 12-15 weeks of systemic treatment in adult psoriasis patients overall, by sex and absence of prior treatment, 2016-2019^a

Without prior treatment

Proteobacteria	4.45 (-0.14, 9.04)	4.64 (1.05, 8.22)c	3.39 (0.76, 6.03)b	3.45 (-0.02, 6.92)
Firmicutes	-7.38 (-10.6, -4.11)d	0.00 (-4.96, 4.96)	-7.30 (-9.39, -5.21)d	-0.04 (-3.40, 3.32)
Actinobacteria	0.87 (-1.05, 2.79)	-1.14 (-3.22, 0.93)	1.03 (-0.26, 2.33)	-1.79 (-3.59, 0.01)
Bacteroidetes	-0.95 (-3.39, 1.49)	-1.85 (-4.63, 0.93)	-0.03 (-1.24, 1.19)	-0.57 (-2.13, 0.98)

Abbreviations: beta, beta coefficient estimate in median regression models; CI, confidence interval for beta coefficient

a. Age-, sex-, absence of prior treatment, study year-adjusted in baseline models; follow-up duration was also accounted for in the longitudinal models; all comparisons excluded data from 2015-2016, during which no control subjects were enrolled

b. P < 0.05

c. P ≤ 0.01

d. $P \le 0.001$

Relative Abundance (%)	Therape	Clinical Assessment	
	TNF-a	Nonbiologics	Severity (PASI > 10)
Baseline	beta (95%CI)	beta (95%CI)	beta (95%CI)
Proteobacteria	-6.98 (-12.2, -1.73)b	0.62 (-4.04, 5.28)	-1.48 (-4.23, 1.26)
Firmicutes	1.27 (-2.57, 5.11)	7.83 (4.26, 10.5)d	0.93 (-1.49, 3.35)
Actinobacteria	-0.63 (-1.79, 0.52)	-0.53 (-1.52, 2.59)	-0.60 (-1.93, 0.72)
Bacteroidetes	0.46 (-2.45, 3.37)	-2.13 (-3.99, -0.27)c	-0.76 (-2.86, 1.34)
Baseline to 12-15 wk			Response (PASI 75)
Proteobacteria	-1.67 (-4.40, 1.06)	0.84 (-1.94, 3.62)	-1.08 (-3.51, 1.35)
Firmicutes	0.10 (-2.06, 2.26)	4.15 (0.79, 7.52)c	0.30 (-1.73, 2.32)
Actinobacteria	-0.73 (-1.50, 0.03)	0.65 (-0.73, 2.03)	-0.75 (-1.68, 0.19)
Bacteroidetes	0.13 (-1.45, 1.71)	-1.47 (-2.49, -0.45)b	-0.50 (-1.68, 0.69)

Table 3. Adjusted associations between phylum-level relative abundances of lesional microbiota and therapeutic class or clinical outcome at baseline and over time in psoriasis patients, 2015-2019^a

Abbreviations: Anti-ILAbs, anti-interleukin monoclonal antibodies; beta, beta coefficient estimate in median regression models; CI, confidence interval for beta coefficient; PASI, psoriasis area severity index

a. Age-, sex-, absence of prior treatment, study year, abd follow-up duration-adjusted quantile regression models; baseline PASI scores were also adjusted in evaluating associations with clinical responses; reference group was patients using anti-ILAbs in comparisons by therapeutic class

b. P < 0.01

c. P < 0.05

d. $P \le 0.001$

	Therapeutic Class		Clinical Assessment
beta (95%CI)	TNF-a Inhibitors Nonbiologics		Severity (PASI > 10)
Baseline			
Observed OTU	4.4 (-7.9, 16.7)	-6.8 (-19.9, 6.4)	-1.0 (-11.0, 9.1)
Chao1	18.9 (-4.5, 42.3)	15.3 (-26.3, 56.9)	-13.9 (-30.0, 2.1)
Shannon D	-0.23 (-0.49, 0.03)	0.08 (-0.19, 0.36)	-0.07 (-0.19, 0.06)
Shannon E	-0.04 (-0.08, 0.01)	0.04 (0.01, 0.07)	-0.01 (-0.03, 0.02)
Baseline to 12-15 wk			Response (PASI 75)
Observed OTU	-3.8 (-10.6, 3.0)	-9.0 (-25.0, 7.0)	-6.8 (-14.0, 0.4)
Chao1	-10.2 (-28.0, 7.6)	-6.3 (-30.9, 18.3)	-15.1 (-27.0, -3.3)c
Shannon D	-0.21 (-0.37, -0.06)b	0.09 (-0.04, 0.22)	-0.07 (-0.15, 0.003)
Shannon E	-0.02 (-0.04, 0.004)	0.03 (0.01, 0.06)b	0.01 (-0.02, 0.03)

Table 4. Adjusted associations between genus-level alpha-diversity measures of lesional microbiota and therapeutic class or clinical assessment in adult psoriasis patients based at baseline and longitudinally, 2015-2019^a

Abbreviations: Anti-ILAbs, anti-interleukin monoclonal antibodies; beta, beta coefficient estimate in median regression models; CI, confidence interval for beta coefficient; PASI, psoriasis area severity index; PASI 75, reduction of PASI at follow-up > 75% of baseline PASI; OTU, operational taxonomy unit; Shannon D, Shannon diversity index; Shannon E, Shannon evenness index

a. Age-, sex-, absence of prior treatment, study year-adjusted quantile regression models; baseline PASI scores were also adjusted in longitudinally evaluating associations with clinical responses; reference group was patients using anti-ILAbs in comparisons by therapeutic class

b. P < 0.01

c. P < 0.05





Alpha Diversity

